Metabolomics in diabetes

Clinica Chimica Acta

Volumn 429, Issue , 2014, Pages 106-110

  Zhang, Ai hua ^a   Qiu, Shi ^a   Xu, Hong ying ^a   Sun, Hui ^a   Wang, Xi jun ^a  

^a HEILONGJIANG UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Biomarkers; Diabetes; Diagnosis; Metabolites; Metabolomics

Indexed keywords

2 HYDROXY 2 METHYLPROPIONIC ACID; ACETYLCARNITINE; AMIDE; BETAINE; BIOLOGICAL MARKER; BUTYRIC ACID; CARNITINE; CITRIC ACID; DECANOYLCARNITINE; GLUCOSE; GLUCURONOLACTONE; GLUTAMIC ACID; GLYCINE; GLYCOSYLATED HEMOGLOBIN; INSULIN; ISOBUTYRIC ACID DERIVATIVE; KYNURENIC ACID; LACTIC ACID; LINOLEIC ACID; LONG CHAIN FATTY ACID; LYSINE; LYSOPHOSPHATIDYLCHOLINE; MALTOSE; N METHYL 2 PYRIDONE 5 CARBOXAMIDE; N METHYLNICOTINAMIDE; PALMITIC ACID; PIPECOLIC ACID; UNCLASSIFIED DRUG; URATE; VALINE;

CLINICAL FEATURE; EARLY DIAGNOSIS; HUMAN; MASS SPECTROMETRY; MEDICAL TECHNOLOGY; METABOLITE; METABOLOME; METABOLOMICS; MOLECULAR WEIGHT; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

BIOMARKERS; DIABETES; DIAGNOSIS; METABOLITES; METABOLOMICS;

BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; HUMANS; METABOLOMICS;

EID: 84890819283     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.11.037     Document Type: Review

References (52)

1. Burke J., Kovacs B., Borton L., Sander S. Health care utilization and costs in type 2 diabetes mellitus and their association with renal impairment. Postgrad Med 2012, 124(2):77-91.
2. Lu H., Yang Y., Allister E.M., Wijesekara N., Wheeler M.B. The identification of potential factors associated with the development of type 2 diabetes: a quantitative proteomics approach. Mol Cell Proteomics 2008, 7(8):1434-1451.
3. Qin J., Li Y., Cai Z., Li S., Zhu J., Zhang F. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 2012, 490(7418):55-60.
4. Sharma A., Chavali S., Mahajan A., Tabassum R., Banerjee V., Tandon N., et al. Genetic association, post-translational modification, and protein-protein interactions in Type 2 diabetes mellitus. Mol Cell Proteomics 2005, 4(8):1029-1037.
5. Polidori D., Sha S., Ghosh A., Plum-Mörschel L., Heise T., Rothenberg P. Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2013, 98(5):E867-E871.
6. Kahn S.E., Hull R.L., Utzschneider K.M. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006, 444(7121):840-846.
7. Samuel V.T., Beddow S.A., Iwasaki T., Zhang X.M., Chu X., Still C.D., et al. Fasting hyperglycemia is not associated with increased expression of PEPCK or G6Pc in patients with Type 2 diabetes. Proc Natl Acad Sci U S A 2009, 106(29):12121-12126.
8. Rosengren A.H., Jokubka R., Tojjar D., Granhall C., Hansson O., Li D.Q., et al. Overexpression of alpha2A-adrenergic receptors contributes to type 2 diabetes. Science 2010, 327(5962):217-220.
9. Zhao Y.Y. Metabolomics in chronic kidney disease. Clin Chim Acta 2013, 422:59-69.
10. Zhang A.H., Sun H., Sun W.J., Jiao G.Z., Wang X.J. Trajectory analysis of metabolomics profiling in liver injured rats using ultra-performance liquid chromatography coupled with mass spectrometry. Anal Methods 2013, 5(19):5294-5301.
11. Zhang A.H., Sun H., Qiu S., Wang X.J. Metabolomics in noninvasive breast cancer. Clin Chim Acta 2013, 424:3-7.
12. Zhang A.H., Sun H., Yan G.L., Yuan Y., Han Y., Wang X.J. Metabolomics study of type 2 diabetes using ultra-performance LC-ESI/quadrupole-TOF high-definition MS coupled with pattern recognition methods. J Physiol Biochem 2013, 10.1007/s13105-013-0286-z.
13. Zhang A., Sun H., Yan G., Han Y., Ye Y., Wang X. Urinary metabolic profiling identifies a key role for glycocholic acid in human liver cancer by ultra-performance liquid-chromatography coupled with high-definition mass spectrometry. Clin Chim Acta 2013, 418:86-90.
14. Zhang A., Sun H., Han Y., Yuan Y., Wang P., Song G., et al. Exploratory urinary metabolic biomarkers and pathways using UPLC-Q-TOF-HDMS coupled with pattern recognition approach. Analyst 2012, 137(18):4200-4208.
15. Yuan M., Breitkopf S.B., Yang X., Asara J.M. A positive/negative ion-switching, targeted mass spectrometry-based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue. Nat Protoc 2012, 7:872-881.
16. Zhang A., Sun H., Wu X., Wang X. Urine metabolomics. Clin Chim Acta 2012, 414:65-69.
17. Zhang T., Wu X., Yin M., Fan L., Zhang H., Zhao F., et al. Discrimination between malignant and benign ovarian tumors by plasma metabolomic profiling using ultra performance liquid chromatography/mass spectrometry. Clin Chim Acta 2012, 413(9-10):861-868.
18. Zheng S., Yu M., Lu X., Huo T., Ge L., Yang J., et al. Urinary metabonomic study on biochemical changes in chronic unpredictable mild stress model of depression. Clin Chim Acta 2010, 411(3-4):204-209.
19. Zhang A.H., Sun H., Han Y., Yan G.L., Yuan Y., Song G.C., et al. Ultraperformance liquid chromatography-mass spectrometry based comprehensive metabolomics combined with pattern recognition and network analysis methods for characterization of metabolites and metabolic pathways from biological data sets. Anal Chem 2013, 85(15):7606-7612.
20. Holmes E., Loo R.L., Stamler J., Bictash M., Yap I.K., Chan Q., et al. Human metabolic phenotype diversity and its association with diet and blood pressure. Nature 2008, 453:396-401.
21. Zhang A.H., Sun H., Qiu S., Wang X.J. NMR-based metabolomics coupled with pattern recognition methods in biomarker discovery and disease diagnosis. Magn Reson Chem 2013, 51(9):549-556.
22. Sreekumar A., Poisson L.M., Rajendiran T.M., Khan A.P., Cao Q., Yu J., et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009, 457:910-914.
23. Huang Y., Tian Y., Li G., Li Y., Yin X., Peng C., et al. Discovery of safety biomarkers for realgar in rat urine using UFLC-IT-TOF/MS and 1H NMR based metabolomics. Anal Bioanal Chem 2013, 405(14):4811-4822.
24. Zhang A.H., Wang P., Sun H., Yan G.L., Han Y., Wang X.J. High-throughput ultra-performance liquid chromatography-mass spectrometry characterization of metabolites guided by a bioinformatics program. Mol Biosyst 2013, 9(9):2259-2265.
25. Ugarte M., Brown M., Hollywood K.A., Cooper G.J., Bishop P.N., Dunn W.B. Metabolomic analysis of rat serum in streptozotocin-induced diabetes and after treatment with oral triethylenetetramine (TETA). Genome Med 2012, 4(4):35.
26. Brezar V., Carel J.C., Boitard C., Mallone R. Beyond the hormone: insulin as an autoimmune target in type 1 diabetes. Endocr Rev 2011, 32(5):623-669.
27. Mihalik S.J., Michaliszyn S.F., de las Heras J., Bacha F., Lee S., Chace D.H., et al. Metabolomic profiling of fatty acid and amino acid metabolism in youth with obesity and type 2 diabetes: evidence for enhanced mitochondrial oxidation. Diabetes Care 2012, 35(3):605-611.
28. McKillop A.M., Flatt P.R. Emerging applications of metabolomic and genomic profiling in diabetic clinical medicine. Diabetes Care 2011, 34(12):2624-2630.
29. Abdul-Ghani M.A., Norton L., Defronzo R.A. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev 2011, 32(4):515-531.
30. Wang X., Zhang S., Zhang A., Yan G., Wu X., Han Y., et al. Metabolomics study of type 2 diabetes and therapeutic effects of Tianqijiangtang-capsule using ultra-performance liquid chromatography/electrospray ionization quadruple time-of-flight mass spectrometry. Anal Methods 2013, 5:2218-2226.
31. Dutta T., Chai H.S., Ward L.E., Ghosh A., Persson X.M., Ford G.C., et al. Concordance of changes in metabolic pathways based on plasma metabolomics and skeletal muscle transcriptomics in type 1 diabetes. Diabetes 2012, 61(5):1004-1016.
32. Wei H., Pasman W., Rubingh C., Wopereis S., Tienstra M., Schroen J., et al. Urine metabolomics combined with the personalized diagnosis guided by Chinese medicine reveals subtypes of pre-diabetes. Mol Biosyst 2012, 8(5):1482-1491.
33. Lanza I.R., Zhang S., Ward L.E., Karakelides H., Raftery D., Nair K.S. Quantitative metabolomics by H-NMR and LC-MS/MS confirms altered metabolic pathways in diabetes. PLoS One 2010, 5(5):e10538.
34. Huo T., Cai S., Lu X., Sha Y., Yu M., Li F. Metabonomic study of biochemical changes in the serum of type 2 diabetes mellitus patients after the treatment of metformin hydrochloride. J Pharm Biomed Anal 2009, 49(4):976-982.
35. Tsutsui H., Maeda T., Min J.Z., Inagaki S., Higashi T., Kagawa Y., et al. Biomarker discovery in biological specimens (plasma, hair, liver and kidney) of diabetic mice based upon metabolite profiling using ultra-performance liquid chromatography with electrospray ionization time-of-flight mass spectrometry. Clin Chim Acta 2011, 412(11-12):861-872.
36. Connor S.C., Hansen M.K., Corner A., Smith R.F., Ryan T.E. Integration of metabolomics and transcriptomics data to aid biomarker discovery in type 2 diabetes. Mol Biosyst 2010, 6(5):909-921.
37. Floegel A., Stefan N., Yu Z., Mühlenbruch K., Drogan D., Joost H.G., et al. Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes 2013, 62(2):639-648.
38. Newgard C.B. Interplay between lipids and branched-chain amino acids in development of insulin resistance. Cell Metab 2012, 15(5):606-614.
39. Ha C.Y., Kim J.Y., Paik J.K., Kim O.Y., Paik Y.H., Lee E.J., et al. The association of specific metabolites of lipid metabolism with markers of oxidative stress, inflammation and arterial stiffness in men with newly diagnosed type 2 diabetes. Clin Endocrinol (Oxf) 2012, 76(5):674-682.
40. Zhu C., Liang Q.L., Hu P., Wang Y.M., Luo G.A. Phospholipidomic identification of potential plasma biomarkers associated with type 2 diabetes mellitus and diabetic nephropathy. Talanta 2011, 85(4):1711-1720.
41. Patterson A.D., Bonzo J.A., Li F., Krausz K.W., Eichler G.S., Aslam S., et al. Metabolomics reveals attenuation of the SLC6A20 kidney transporter in nonhuman primate and mouse models of type 2 diabetes mellitus. J Biol Chem 2011, 286(22):19511-19522.
42. Wang T.J., Larson M.G., Vasan R.S., Cheng S., Rhee E.P., McCabe E., et al. Metabolite profiles and the risk of developing diabetes. Nat Med 2011, 17(4):448-453.
43. Wang-Sattler R., Yu Z., Herder C., Messias A.C., Floegel A., He Y., et al. Novel biomarkers for pre-diabetes identified by metabolomics. Mol Syst Biol 2012, 8:615.
44. Fiehn O., Garvey W.T., Newman J.W., Lok K.H., Hoppel C.L., Adams S.H. Plasma metabolomic profiles reflective of glucose homeostasis in non-diabetic and type 2 diabetic obese African-American women. PLoS One 2010, 5(12):e15234.
45. Salek R.M., Maguire M.L., Bentley E., Rubtsov D.V., Hough T., Cheeseman M., et al. A metabolomic comparison of urinary changes in type 2 diabetes in mouse, rat, and human. Physiol Genomics 2007, 29(2):99-108.
46. Suhre K., Meisinger C., Döring A., Altmaier E., Belcredi P., Gieger C., et al. Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting 2010 Nov 11, 5(11):e13953.
47. Zhao L.C., Zhang X.D., Liao S.X., Gao H.C., Wang H.Y., Lin D.H. A metabonomic comparison of urinary changes in Zucker and GK rats. J Biomed Biotechnol 2010, 2010:431894.
48. Bao Y., Zhao T., Wang X., Qiu Y., Su M., Jia W., et al. Metabonomic variations in the drug-treated type 2 diabetes mellitus patients and healthy volunteers. J Proteome Res 2009, 8(4):1623-1630.
49. Zhang X., Wang Y., Hao F., Zhou X., Han X., Tang H., et al. Human serum metabonomic analysis reveals progression axes for glucose intolerance and insulin resistance statuses. J Proteome Res 2009, 8(11):5188-5195.
50. Li X., Xu Z., Lu X., Yang X., Yin P., Kong H., et al. Comprehensive two-dimensional gas chromatography/time-of-flight mass spectrometry for metabonomics: biomarker discovery for diabetes mellitus. Anal Chim Acta 2009, 633(2):257-262.
51. Woo H.M., Kim K.M., Choi M.H., Jung B.H., Lee J., Kong G., et al. Mass spectrometry based metabolomic approaches in urinary biomarker study of women's cancers. Clin Chim Acta 2009, 400(1-2):63-69.
52. Tomita M., Kami K. Cancer. Systems biology, metabolomics, and cancer metabolism. Science 2012, 336(6084):990-991.